Royalty Pharma PLC (RPRX) has disclosed a new risk, in the Regulation category. The planned internalization of Royalty Pharma LLC by RP Holdings, ...

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word (s): Quarterly / Interim Statement/Quarter Results SCHOTT Pharma records good start into fiscal year and confirms full year outlook 13.02.2025 / ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), ...

Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...

Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies. You can obtain detailed information about the use of cookies ...

CNW/ - Canada Pension Plan Investment Board (CPP Investments) ended its third quarter on December 31, 2024, with net assets ...

Arabian Business unveils its 2025 list of 100 Most Inspiring Women, showcasing the female leaders transforming the Middle ...

The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential ...

Enter Telegraph 25, the list of our favourite investment funds. It is a mixture of funds that we believe will grow your money ...

Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity firm Bain Capital in a deal worth 510 billion yen ($3.36 billion) as it ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

The pharma giant hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than forecast fourth ...